Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC) -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (296)	5/11/1998 2:04:00 PM
From: squetch	Read Replies (1) \| Respond to of 717

From your description it sounds like on of those kind of CNBC reports that run five times in 24 hours? I would love to see it.

To: Henry Niman who wrote (296)	5/11/1998 6:40:00 PM
From: Biomaven	Read Replies (2) \| Respond to of 717

Henry, The report seemed strange because no one from the company was interviewed and the report seemed very positive about news that had not come out yet. Well in some sense the news is out already. First, this is a follow-on report with more patients, but the initial patient population did so well that the combined group is almost certain to do well also. Second, the abstract title is available on the web with the magic words "improved survival" in it. Third, the abstract itself is already available to ASCO members, and presumably also to the analysts that follow this stock. That Gd-Tex is an exciting drug with tremendous potential is nothing new. This is the drug that the H&Q analyst covering PCYC described as potentially the biggest selling cancer drug ever. I thought there might be a pop with the ASCO conference coming up, but I didn't expect it before the conference. If the May calls didn't expire a few days before the presentation I would have loaded up with them; as it is I bought a few more-distant calls last week to add to my long-established PCYC position. Peter